Results 251 to 260 of about 99,309 (305)

Lower Tuberculosis Incidence Among People With HIV Who Completed Isoniazid Preventive Therapy in Ukraine, a High-Burden Multidrug-Resistant Tuberculosis Setting: A Retrospective Cohort Study. [PDF]

Clin Infect Dis
Sodeke O, Shah NS, Pals S, Riabokon S, Samsonova O, Mishara F, Doan I, Hetman L, Barzilay E, Podolchak N, Da Silva J.   +10 more
europepmc   +1 more source

Genomic insights into extrapulmonary tuberculosis reveal enrichment of lineage 2 with high drug resistance in specific clinical phenotypes

Sharma K, Bandari A, Manjunath GK, Rastogi M, Babu AS, Ponnusamy P, Vasanthaiah S, Vasudevan K, Yadav P, George J, Kumar A, Sharma J, Sharma A, Modi M, Gupta A, Singh R, Sinha SK, Dhillon MS, Sharma M, Sharma V, Nada R, Sharma N, Pandey A, Verma R.   +23 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Isoniazid Interactions

Southern Medical Journal, 1985
Isoniazid is an antituberculous drug that is usually administered for nine to 12 months. The potential for clinically important interactions exists because this drug is a potent inhibitor of drug metabolism. Studies and case reports have shown that isoniazid inhibits the metabolism of several drugs, including phenytoin, carbamazepine, anticoagulants ...
A M, Baciewicz, T H, Self
openaire   +2 more sources

Isoniazid

Reactions Weekly, 2021
  +8 more sources